Helus ‘welcomes’ Executive Order for accelerating psychedelic research

Helus Pharma (HELP) welcomed the White House Executive Order aimed at accelerating research, regulatory pathways, and patient access to psychedelic treatments. “The Executive Order reflects growing recognition of the urgent need for new treatment options in serious mental health conditions and the importance of advancing innovative therapies through rigorous, research-based development,” said Eric So, Interim Chief Executive Officer of Helus Pharma. “Policy momentum is meaningful, but the future of this field will ultimately be determined by the strength of the clinical evidence and the ability to deliver safe, reliable treatments at scale.”